The price of INVO Fertility, Inc. (NASDAQ: IVF) saw a noteworthy uptick of 355.44% in Tuesday's premarket session. With the last recorded RSI at 32 the stock is eyeing a move to the $50 resistance amidst bullish momentum.
The 61.8% Fib level is feasible for
IVF shares to capitalize on.
In recent news, INVO Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
Signing of definitive purchase agreement represents critical next step in completing previously announced acquisition.
About IVF
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body.
The 61.8% Fib level is feasible for
IVF shares to capitalize on. In recent news, INVO Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
Signing of definitive purchase agreement represents critical next step in completing previously announced acquisition.
About IVF
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body.
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.